Your session is about to expire
← Back to Search
RO7296682 + Atezolizumab for Advanced Cancer
Study Summary
This trial will test if a new drug is safe and works well with another drug to treat people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had another type of cancer within the past two years.You have complications with healing wounds.You have had a severe skin reaction in the past called Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS.You have a current or past autoimmune disease or a weakened immune system.You have advanced or metastatic solid tumors that have not responded to standard treatments, you cannot tolerate standard treatments, or standard treatments are not suitable for you.
- Group 1: Part I
- Group 2: Part II
- Group 3: Part III (Exploratory)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical centers are enrolled in the clinical trial?
"As of now, the trial is enrolling participants from 5 clinical sites. Toronto, Vancouver and Ottawa are among them as well as 2 other locales. To reduce travelling needs should you choose to join this study, picking a centre closest to your residence would be most beneficial."
What medical conditions has RO7296682 been demonstrated to be effective in addressing?
"RO7296682 is primarily used in the treatment of small cell lung cancer (sclc). Additionally, this drug can be deployed to treat a variety of malignancies and postoperative situations."
What other research efforts have been made regarding RO7296682?
"The initial trials of RO7296682 began at SCRI Tennessee Oncology Chattanooga in 2008, with 82 studies already completed. Currently, 350 active experiments are being conducted across the world, many of which based out of Toronto, Ontario."
In what size population is this research being conducted?
"The trial's sponsor, Hoffmann-La Roche, requires the recruitment of 180 individuals that meet the criteria outlined in their protocol. These patients will be recruited from various locations such as Princess Margaret Cancer Centre and MD Anderson Cancer Center."
Does this research project bring something new to the table?
"Currently, there are 350 research projects related to RO7296682 operating in 74 nations and 1646 cities. Hoffmann-La Roche launched the initial trial in 2008 with 720 participants; since then, 82 further studies have been conducted up to Phase 2 drug approval stage."
Does RO7296682 offer users any risks or side effects?
"RO7296682 has yet to go through extensive clinical testing, so it is given a score of 1 for safety. Thus far, only limited data exists outlining its efficacy and security."
Are fresh participants still being accepted for this research endeavor?
"Affirmative, clinicaltrials.gov confirms that this medical trial began recruitment on April 1st 2021 and is still actively searching for participants as of November 16th 2022. 180 patients need to be enrolled from 5 different sites."
Share this study with friends
Copy Link
Messenger